Literature DB >> 19236488

Reprint: Good laboratory practice: preventing introduction of bias at the bench.

Malcolm R Macleod1, Marc Fisher, Victoria O'Collins, Emily S Sena, Ulrich Dirnagl, Philip M W Bath, Alistair Buchan, H Bart van der Worp, Richard J Traystman, Kazuo Minematsu, Geoffrey A Donnan, David W Howells.   

Abstract

As a research community, we have failed to demonstrate that drugs that show substantial efficacy in animal models of cerebral ischemia can also improve outcome in human stroke. Accumulating evidence suggests that this may be due, at least in part, to problems in the design, conduct and reporting of animal experiments, which create a systematic bias resulting in the overstatement of neuroprotective efficacy. Here, we set out a series of measures to reduce bias in the design, conduct and reporting of animal experiments modeling human stroke.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19236488     DOI: 10.1111/j.1747-4949.2009.00241.x

Source DB:  PubMed          Journal:  Int J Stroke        ISSN: 1747-4930            Impact factor:   5.266


  11 in total

1.  Differential effects of hypothermia on neurovascular unit determine protective or toxic results: Toward optimized therapeutic hypothermia.

Authors:  Patrick D Lyden; Jessica Lamb; Shweta Kothari; Shahed Toossi; Paul Boitano; Padmesh S Rajput
Journal:  J Cereb Blood Flow Metab       Date:  2018-11-21       Impact factor: 6.200

2.  Neuroprotection and vasculoprotection using genetically targeted protease-ligands.

Authors:  Padmesh S Rajput; Jessica A Lamb; Jose Á Fernández; Jilin Bai; Benedict R Pereira; I-Farn Lei; Jennifer Leung; John H Griffin; Patrick D Lyden
Journal:  Brain Res       Date:  2019-03-14       Impact factor: 3.252

3.  Dealing with publication bias in translational stroke research.

Authors:  Shimin Liu
Journal:  J Exp Stroke Transl Med       Date:  2009

4.  RODENT STROKE MODEL GUIDELINES FOR PRECLINICAL STROKE TRIALS (1ST EDITION).

Authors:  Shimin Liu; Gehua Zhen; Bruno P Meloni; Kym Campbell; H Richard Winn
Journal:  J Exp Stroke Transl Med       Date:  2009-01-01

5.  Quality and validity of large animal experiments in stroke: A systematic review.

Authors:  Leona Kringe; Emily S Sena; Edith Motschall; Zsanett Bahor; Qianying Wang; Andrea M Herrmann; Christoph Mülling; Stephan Meckel; Johannes Boltze
Journal:  J Cereb Blood Flow Metab       Date:  2020-06-23       Impact factor: 6.200

6.  The Stroke Preclinical Assessment Network: Rationale, Design, Feasibility, and Stage 1 Results.

Authors:  Patrick D Lyden; Francesca Bosetti; Márcio A Diniz; André Rogatko; James I Koenig; Jessica Lamb; Karisma A Nagarkatti; Ryan P Cabeen; David C Hess; Pradip K Kamat; Mohammad B Khan; Kristofer Wood; Krishnan Dhandapani; Ali S Arbab; Enrique C Leira; Anil K Chauhan; Nirav Dhanesha; Rakesh B Patel; Mariia Kumskova; Daniel Thedens; Andreia Morais; Takahiko Imai; Tao Qin; Cenk Ayata; Ligia S B Boisserand; Alison L Herman; Hannah E Beatty; Sofia E Velazquez; Sebastian Diaz-Perez; Basavaraju G Sanganahalli; Jelena M Mihailovic; Fahmeed Hyder; Lauren H Sansing; Raymond C Koehler; Steven Lannon; Yanrong Shi; Senthilkumar S Karuppagounder; Adnan Bibic; Kazi Akhter; Jaroslaw Aronowski; Louise D McCullough; Anjali Chauhan; Andrew Goh
Journal:  Stroke       Date:  2022-03-31       Impact factor: 10.170

Review 7.  Update of the stroke therapy academic industry roundtable preclinical recommendations.

Authors:  Marc Fisher; Giora Feuerstein; David W Howells; Patricia D Hurn; Thomas A Kent; Sean I Savitz; Eng H Lo
Journal:  Stroke       Date:  2009-02-26       Impact factor: 7.914

Review 8.  Bringing rigour to translational medicine.

Authors:  David W Howells; Emily S Sena; Malcolm R Macleod
Journal:  Nat Rev Neurol       Date:  2013-11-19       Impact factor: 42.937

9.  Authorization of Animal Experiments Is Based on Confidence Rather than Evidence of Scientific Rigor.

Authors:  Lucile Vogt; Thomas S Reichlin; Christina Nathues; Hanno Würbel
Journal:  PLoS Biol       Date:  2016-12-02       Impact factor: 8.029

10.  Glibenclamide, a Sur1-Trpm4 antagonist, does not improve outcome after collagenase-induced intracerebral hemorrhage.

Authors:  Cassandra M Wilkinson; Paul S Brar; Celine J Balay; Frederick Colbourne
Journal:  PLoS One       Date:  2019-05-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.